10-20-2021, 06:17 PM
CHRS: A heavily shorted biotech with major catalysts upcoming
<!-- SC_OFF --><div class="md"><p>CHRS: A heavily shorted biotech with major catalysts upcoming</p> <p>Coherus: 11% short interest, down from 14% recently </p> <p>One product on market, a version of the cancer drug neulasta. Sales were down due to covid but still reached $88 million last quarter </p> <p>Catalysts: co-owner of a version of the eye medication lucentis, applied for fda approval, set for aug. 2</p> <p>Company waiting on fda approval in December of a version of humira, an anti-inflammation drug with $18 billion in annual sales. If approved, sales start July 2023.</p> <p>Waiting on springtime approval of tori, an immunology drug targeting many different tumor types </p> <p>2022 submission to fda of a version of the cancer drug avastin and an on-body device like neulasta on-pro </p> <p>So many exciting things happening for this company. Could be $100 a share in two years. A short squeeze would be amazing due to the relatively small float. In addition, this stock has a healthy balance sheet and no expectations for dilution.</p> </div><!-- SC_ON --> submitted by <a href="https://www.reddit.com/user/jixxer1112"> /u/jixxer1112 </a> <br/> <span><a href="https://www.reddit.com/r/investing/comments/qbmu9i/chrs_a_heavily_shorted_biotech_with_major/">[link]</a></span> <span><a href="https://www.reddit.com/r/investing/comments/qbmu9i/chrs_a_heavily_shorted_biotech_with_major/">[comments]</a></span>Kind Regards R
<!-- SC_OFF --><div class="md"><p>CHRS: A heavily shorted biotech with major catalysts upcoming</p> <p>Coherus: 11% short interest, down from 14% recently </p> <p>One product on market, a version of the cancer drug neulasta. Sales were down due to covid but still reached $88 million last quarter </p> <p>Catalysts: co-owner of a version of the eye medication lucentis, applied for fda approval, set for aug. 2</p> <p>Company waiting on fda approval in December of a version of humira, an anti-inflammation drug with $18 billion in annual sales. If approved, sales start July 2023.</p> <p>Waiting on springtime approval of tori, an immunology drug targeting many different tumor types </p> <p>2022 submission to fda of a version of the cancer drug avastin and an on-body device like neulasta on-pro </p> <p>So many exciting things happening for this company. Could be $100 a share in two years. A short squeeze would be amazing due to the relatively small float. In addition, this stock has a healthy balance sheet and no expectations for dilution.</p> </div><!-- SC_ON --> submitted by <a href="https://www.reddit.com/user/jixxer1112"> /u/jixxer1112 </a> <br/> <span><a href="https://www.reddit.com/r/investing/comments/qbmu9i/chrs_a_heavily_shorted_biotech_with_major/">[link]</a></span> <span><a href="https://www.reddit.com/r/investing/comments/qbmu9i/chrs_a_heavily_shorted_biotech_with_major/">[comments]</a></span>Kind Regards R